Luliconazole Patent Expiration
Luliconazole is Used for treating fungal infections. It was first introduced by Bausch Health Us Llc
Luliconazole Patents
Given below is the list of patents protecting Luliconazole, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Luzu | US8980931 | Method of evaluating pharmaceutical preparation containing luliconazole and index substance | Apr 28, 2034 | Bausch |
| Luzu | US9012484 | Crystal and pharmaceutical preparation containing the same crystal | Sep 06, 2033 | Bausch |
| Luzu | US9199977 | Crystal having crystal habits and pharmaceutical composition obtained by processing the crystal | Sep 06, 2033 | Bausch |
| Luzu | US9453006 | Crystalline form having specific crystal habit and pharmaceutical composition containing this crystalline form as active ingredient | Sep 06, 2033 | Bausch |
| Luzu | US5900488 | Method for treating mycosis using imidazolylacetonitrile derivatives |
Jan 18, 2020
(Expired) | Bausch |
Luliconazole's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Luliconazole:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
| ||||
| Safety and Tolerability Study of SKX-16 in Subjects With Moderate to Severe Distal Subungual Onychomycosis | SATO Pharmaceutical Co., Ltd. | NA |
COMPLETED
(Aug 1, 2026)
| PHASE1 |